Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 900
- Registration Number
- NCT06574984
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 500
- Registration Number
- NCT06571383
- Locations
- 🇨🇦
Maison de Sante Prevention, Montreal, Quebec, Canada
🇵🇱Górnośląskie Centrum Zdrowia Dziecka Im. Św. Jana Pawla II Samodzielny Publiczny Szpital Kliniczny Nr 6 SUM w Katowicach, Katowice, Poland
🇺🇸Neighborhood Healthcare, Escondido, California, United States
A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 64
- Registration Number
- NCT06567041
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT06559527
- Locations
- 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany
A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 73
- Registration Number
- NCT06542536
- Locations
- 🇺🇸
Altasciences Clinical LA, Inc., Cypress, California, United States
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 432
- Registration Number
- NCT06542874
- Locations
- 🇺🇸
Encore Medical Research LLC, Hollywood, Florida, United States
🇺🇸Clinical Research Associates, Nashville, Tennessee, United States
🇺🇸Southern Cal Clinical Research, Santa Ana, California, United States
A Research Study to See How Much CagriSema (1.0 mg Once Weekly) Lowers Blood Sugar and Body Weight Compared to Tirzepatide (5 mg Once Weekly) in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1000
- Registration Number
- NCT06534411
- Locations
- 🇺🇸
Cahaba Research, Pelham, Alabama, United States
🇺🇸Velocity Clinical Research-Phoenix, Phoenix, Arizona, United States
🇺🇸AES Tucson DRS, Tucson, Arizona, United States
Insulin Initiation and Adherence Behaviours: a Cross Sectional Survey of Indian HCPs & Patients With Type 2 Diabetes
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 752
- Registration Number
- NCT06517784
- Locations
- 🇮🇳
Novo Nordisk India, Bangalore, India
A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 37
- Registration Number
- NCT06513104
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 209
- Registration Number
- NCT06507475
© Copyright 2024. All Rights Reserved by MedPath